{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:51:05Z","timestamp":1791280265322,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Nationale contre le cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009406","name":"CHU de Nantes","doi-asserted-by":"crossref","award":["2008-004677-18"],"award-info":[{"award-number":["2008-004677-18"]}],"id":[{"id":"10.13039\/501100009406","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009406","name":"CHU de Nantes","doi-asserted-by":"crossref","award":["BRD 07\/11-U"],"award-info":[{"award-number":["BRD 07\/11-U"]}],"id":[{"id":"10.13039\/501100009406","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clgc.2015.01.005","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T15:47:32Z","timestamp":1421855252000},"page":"e209-e215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Gu\u00e9rin Instillations for Bladder\u00a0Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"J\u00e9r\u00f4me","family":"Rigaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire","family":"Devilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Scotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.01.005_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2015.01.005_bib3","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S1166-7087(10)70043-9","article-title":"Recommandations en Onco-Urologie 2010: Tumeurs urotheliales","volume":"20","author":"Pfister","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib4","first-page":"1964","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib5","first-page":"1124","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","article-title":"Systemic immune response after intravesical instillation of bacille Calmette-Gu\u00e9rin (BCG) for superficial bladder cancer","volume":"115","author":"Taniguchi","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clgc.2015.01.005_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.clgc.2015.01.005_bib8","first-page":"59","article-title":"Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"144","author":"Bohle","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2015.01.005_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","article-title":"Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy","volume":"99","author":"Jackson","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clgc.2015.01.005_bib11","first-page":"1248","article-title":"Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy","volume":"144","author":"Prescott","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2015.01.005_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0090-1229(86)90043-7","article-title":"Interleukin-2 production during intravesical bacille Calmette-Gu\u00e9rin therapy for bladder cancer","volume":"40","author":"Ratliff","year":"1986","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.clgc.2015.01.005_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0090-4295(94)90042-6","article-title":"Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy","volume":"43","author":"Balbay","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2015.01.005_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/1043-4666(90)90013-J","article-title":"Detection of urinary TNF, IL 1, and IL\u00a02\u00a0after local BCG immunotherapy for bladder carcinoma","volume":"2","author":"Bohle","year":"1990","journal-title":"Cytokine"},{"key":"10.1016\/j.clgc.2015.01.005_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0165-2478(02)00040-8","article-title":"The anti-tumor activity of bacillus Calmette-Gu\u00e9rin in bladder cancer is associated with an increase in the circulating level of interleukin-2","volume":"81","author":"Magno","year":"2002","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clgc.2015.01.005_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2015.01.005_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2015.01.005_bib18","first-page":"3041","article-title":"Gonzalez de Buitrago JM, Navajo JA. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG","volume":"21","author":"Sanchez-Carbayo","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2015.01.005_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000087163","article-title":"Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin for superficial bladder tumors","volume":"75","author":"Eto","year":"2005","journal-title":"Urol Int"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:12Z","timestamp":1761564312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767315000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1558767315000075"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.01.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Gu\u00e9rin Instillations for Bladder\u00a0Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}